Listed

AVITA Medical, Inc.: Form 10-Q for the period ended Sep 30, 2022

Filed with the SEC on Nov 10, 2022 and accepted by EDGAR at Nov 10, 2022, 16:33 ET.

Share

Management's discussion and analysis

As filed, 25,551 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited consolidated financial statements and related notes appearing elsewhere in this Quarterly Report on Form 10-Q.

Our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated, or indicated in any forward-looking statements. We caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this Quarterly Report on Form 10-Q. In addition, even if our results of operations, financial condition and liquidity, and the development of the industry in which we operate are consistent with the forward-looking statements contained in this Quarterly Report on Form 10-Q, they may not be predictive of results or developments in future periods.

The following information and any forward-looking statements should be considered in light of factors discussed elsewhere in this Quarterly Report on Form 10-Q, including those risks identified under Part II, Item 1A. Risk Factors.

We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date they are made. We disclaim any obligation, except as specifically required by law and the rules of the SEC and the ASX, to publicly update or revise any such statements to reflect any change in our expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.

Overview

The AVITA group of companies (comprising AVITA Medical, Inc. (“AVITA” or the “Company”) and its subsidiaries, including AVITA Medical Pty Limited, previously known as AVITA Medical Limited, (“AVITA Medical”)) (collectively, “AVITA Group” or “we”, “us”, or “our”) is a regenerative medicine company leading the development and commercialization of devices and autologous cellular therapies for skin restoration. The Company’s RECELL® System technology platform harnesses the regenerative properties of a patient’s own skin to create Spray-On Skin™ cells. In September 2018, the United States Food & Drug Administration (“FDA”) granted premarket approval (“PMA”) to the RECELL System for use in the treatment of acute partial-thickness thermal burns or application in combination with meshed autografting for acute full-thickness thermal burn wounds in patients eighteen years and older. Following receipt of our original PMA, we commenced commercialization of the RECELL System in January 2019 in the United States. In June 2021, the FDA expanded its approval to include pediatric acute full-thickness thermal wounds in combination of meshed autografting. In February 2022, the FDA approved a PMA supplement for the RECELL Autologous Cell Harvesting Device, an enhanced ease-of-use device aimed at providing clinicians a more efficient user experience and simplified workflow. In addition, the FDA has granted the Company Investigational Device Exemptions (“IDEs”), which have enabled the Company to initiate pivotal clinical trials to further expand the approval of the RECELL System for the treatment of soft tissue repair and vitiligo. Enrollment of those clinical trials is complete, with topline results recently announced for both the soft tissue repair and vitiligo trials. Results from those studies are intended to support the Company’s pursuit of FDA approval to market the RECELL System in the United States for those indications.

The RECELL System is used to prepare Spray-On Skin Cells using a small amount of a patient’s own skin, providing a new way to treat severe burns, while significantly reducing the amount of donor skin required. The RECELL System is designed to be used at the point of care as a standalone product, or in combination with “skin grafts”, known as split-thickness skin autografts, depending on the depth of the burn injury. The pivotal studies leading to the RECELL System’s FDA PMA for the treatment of acute thermal burns, demonstrated that the RECELL System treated burns using 97.5-percent less donor skin when used alone in second-degree burns, and 32-percent less donor skin when used with autograft for third-degree burns compared to standard of care autografting. In these studies, a statistically significant reduction in donor skin required to treat burn patients with the RECELL System was realized without any associated compromise to healing or safety outcomes. Donor site outcomes from the clinical trial for second-degree burns also revealed a statistically significant reduction in patient-reported pain, increased patient satisfaction and improved scar outcomes.

Our compelling data from randomized, controlled clinical trials conducted at major United States burn centers, health economics modeling, and real-world use globally demonstrate that the RECELL System is a significant advancement over the current standard of care for burn patients and offers benefits in clinical outcomes and cost savings.

The RECELL System has received various approvals and registrations in international markets. The RECELL System is TGA-registered in Australia, received CE-mark approval in Europe, and received Japan’s Pharmaceuticals and Medical Devices Act (“PMDA”) approval for burns in Japan and has begun commercialization. Presently, other than in the U.S. and Japan we are not actively marketing the RECELL System and therefore do not derive material revenue from the RECELL System in Australia, Europe or other markets.

Our website address is www.avitamedical.com (http://www.avitamedical.com). Information contained on our website is not part of or incorporated into this report. We make our periodic reports, together with any amendments, available on our website, free of charge, as soon as reasonably practicable after we electronically file or furnish the reports with the Securities and Exchange Commission (“SEC”) or with the Australian Securities Exchange (“ASX”). The SEC maintains an internet site, www.sec.gov (http://www.sec.gov), which contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC. Copies of announcements made by the Company to the ASX are available on ASX’s website (www.asx.com.au (http://www.asx.com.au)).

Corporate History

AVITA Medical, the former parent company of the AVITA Group, began as a laboratory spin-off in the Australian State of Western Australia. Clinical Cell Culture (“C3”) (being the prior name of AVITA Medical) was formed under the laws of the Commonwealth of Australia in December 1992 and has operated as AVITA Medical since 2008. AVITA Medical’s ordinary shares originally began trading in Australia on the Australian Securities Exchange (“ASX”) on August 9, 1993. AVITA Medical’s American Depositary Shares (“ADSs”) traded over the counter on the OTCQX under the ticker symbol “AVMXY” from May 14, 2012, through September 30, 2019, and its ADSs began trading on the Nasdaq Capital Market on October 1, 2019, under the ticker symbol “RCEL”.

The Company’s CHESS Depositary Interests (“CDIs”) are quoted on the ASX under AVITA Medical’s former ASX ticker code, “AVH”. The Company’s shares of common stock are quoted on Nasdaq under AVITA Medical’s former Nasdaq ticker code, “RCEL”. One share of common stock on Nasdaq is equivalent to five CDIs on the ASX.

COVID-19 Business Update and Risks Associated with COVID-19

The ongoing pandemic caused by the spread of coronavirus (“COVID-19”) has created significant disruptions to the U.S. and global economies and financial markets. The global impact of the pandemic has fluctuated since early 2020. At times, in the United States, state and local governmental authorities have responded by issuing orders, of varying degrees, requiring quarantines, restrictions on travel and minimizing social gathering/interactions and mandatory closures of certain non-essential businesses. Many of the restrictions have been periodically updated as infection rates in the U.S. have risen and fallen, as new variants have emerged, as vaccines have become available, and new information about transmission has been discovered.

In response to the pandemic, we acted swiftly by implementing protocols to ensure continuity of our manufacturing, increasing our safety stock and to provide for the safety of our employees. Early on, our business and operations were impacted by the ongoing effects of the pandemic with restrictions on travel and access to our customers or temporary suspension of treatment of burn patients or re-distribution of those patients to other treatment facilities and resulted in a reduction in the volume of burn procedures using the RECELL following the implementation of those protective measures. In addition, we experienced periodic enrollment cessation in our clinical trials due to COVID-19 as well as having individuals excluded due to contracting the virus.

As of the date of this filing, with the continued overall decrease in COVID-19 infections and hospitalizations we have resumed on-site work schedules for all employees. Thus far, 2022 the impact of COVID-19 has decreased as compared to 2021 for our business and operations; however, COVID-19 pandemic around the world, and particularly in the United States, continues to present risks to the Company. While the COVID-19 pandemic has not materially adversely affected our financial results and business operations through the third quarter ended September 30, 2022, we are unable to predict the impact that COVID-19 will have on our business, operations, and financial results and condition because of the numerous uncertainties created by the unprecedented nature of the pandemic. We are closely monitoring the evolving impact of the pandemic on all aspects of our business. We have implemented a number of measures designed to protect the health and safety of our employees, support our customers and promote business continuity. We continue to evaluate the Company’s liquidity and operational performance, communicate with and monitor the actions of our customers, third-party manufacturers and suppliers, and review our near-term financial performance as we manage the Company through this period of uncertainty.

Results of Operations for the three-months ended September 30, 2022 compared to the three-months ended September 30, 2021.

The table below summarizes the results of our continuing operations for each of the periods presented (in thousands).

Three-Months Ended September 30, 2022 2021 Change ($) % Change Favorable/(Unfavorable)
Revenues $9,092 $7,020 2,072 30%
Cost of sales (1,530) (1,088) (442) (41%)
Gross profit 7,562 5,932 1,630 27%
BARDA income 904 374 530 142%
Operating expenses:
Sales and marketing expenses (5,411) (3,518) (1,893) (54%)
General and administrative expenses (5,004) (5,349) 345 6%
Research and development expenses (3,799) (3,388) (411) (12%)
Total operating expenses (14,214) (12,255) (1,959) (16%)
Operating loss (5,748) (5,949) 201 3%
Interest expense (6) (9) 3 33%
Other income 170 16 154 963%
Loss before income taxes (5,584) (5,942) 358 6%
Income tax expense (4) (6) (2) (33%)
Net loss $(5,588) $(5,948) 360 6%

Total net revenues increased by 30%, or $2.1 million, to $9.1 million, compared to $7.0 million in the corresponding period in the prior year. Our commercial revenue, which excludes BARDA revenue, was $9.0 million in the three-months ended September 30, 2022, an increase of $2.1 million or 30%, compared to $6.9 million in the corresponding period in the prior year. The growth in icommercial revenues was largely driven by deeper penetration within individual customer accounts along with the commencement of commercial sales with our partner COSMOTEC in Japan.

Gross profit margin decreased by 2% to 83% compared to the corresponding period in the prior year.

BARDA income increased by 142%, or $0.5 million, to $0.9 million, compared to $0.4 million for the corresponding period in the prior year. BARDA income consisted of funding from the Biomedical Advanced Research and Development Authority, under the Assistant Secretary for Preparedness and Response, within the U.S. Department of Health and Human Services, under ongoing USG Contract No. HHSO100201500028C. BARDA income increased as a result of funding by BARDA for the pivotal trial for use of the RECELL System for soft tissue reconstruction.

Total operating expenses increased by 16% or $2.0 million to $14.2 million, compared with $12.3 million in the corresponding period in the prior year.

Sales and marketing expenses increased by 54%, or $1.9 million, to $5.4 million, compared to $3.5 million incurred in the corresponding period in the prior year. Higher costs in the current year were primarily attributed to higher salaries and benefits, selling expenses, pre-commercialization costs and share-based compensation expenses. Increase in salaries and benefits primarily resulted from additional field personnel added to deepen penetration within individual customer accounts. Higher selling expenses resulted from an increase in travel costs due to fewer COVID-19 travel restrictions in the current year, along with higher commissions associated with the increase in revenues. Increased pre-commercialization costs are primarily due to planning for future RECELL launches in soft tissue reconstruction and vitiligo. Higher share-based compensation expenses were due to our adoption of a long-term incentive plan to encourage and reward shareholder value creation in the business.

General and administrative expenses decreased by 6%, or $0.3 million, to $5.0 million, compared to $5.3 million incurred in the same period in the prior year. The decrease was primarily due to lower share-based compensation expenses, lower professional fees, partially offset by severance costs associated with the termination of a former executive employee. Lower share-based compensation expenses in the current quarter resulted from certain performance milestones being met in the prior year, along with the reversal of previously recognized expense for unvested awards related to the termination of an executive employee in the current year. Lower professional fees incurred in the current year resulted from the company changing from a fiscal year to a calendar year.

Research and development expenses increased by 12%, or $0.4 million, to $3.8 million, compared to $3.4 million incurred in the same period in the prior year. The increase was a result of ongoing development of next generation devices for more automated preparation of Spray-On Skin Cells The increase was partially offset by lower clinical trial expenses for soft tissue reconstruction and vitiligo as trial participants were in less costly follow-up phases this period compared to more costly recruitment and treatment phases in the prior period.

Results of Operations for the nine-months ended September 30, 2022 compared to the nine-months ended September 30, 2021.

The table below summarizes the results of our continuing operations for each of the periods presented (in thousands).

Nine-Months Ended September 30, 2022 2021 Change ($) % Change Favorable/(Unfavorable)
Revenues $24,966 $26,089 (1,123) (4%)
Cost of sales (4,694) (5,287) 593 11%
Gross profit 20,272 20,802 (530) (3%)
BARDA income 2,189 1,384 805 58%
Operating expenses:
Sales and marketing expenses (15,571) (11,313) (4,258) (38%)
General and administrative expenses (18,009) (16,046) (1,963) (12%)
Research and development expenses (10,478) (11,471) 993 9%
Total operating expenses (44,058) (38,830) (5,228) (13%)
Operating loss (21,597) (16,644) (4,953) (30%)
Interest expense (10) (21) 11 52%
Other income 307 25 282 1128%
Loss before income taxes (21,300) (16,640) (4,660) (28%)
Income tax expense (12) (23) 11 48%
Net loss $(21,312) $(16,663) (4,649) (28%)

Total net revenues decreased by 4%, or $1.1 million, to $25.0 million, compared to $26.1 million in the corresponding period in the prior year. The decrease in the current year revenue was driven by our recognition of $7.8 million in BARDA related revenue in the prior year resulting from our delivery of units to managed inventory for BARDA for emergency response preparedness. Our commercial revenue, which excludes BARDA revenue, increased 35% or $6.5 million to $24.7 million, compared to $18.2 million in corresponding period in the prior year. The growth in commercial revenues was largely driven by an increase in the number of customers ordering as well as the average monthly order size for those customers.

Gross profit margin increased by 1% to 81% compared to the corresponding period in the prior year. In the prior year our gross margins were lower compared to historical periods due to the lower price point associated with units that were delivered to managed inventory for BARDA as the BARDA contract was negotiated prior to establishing a higher price point through commercialization in the United States.

BARDA income increased by 58%, or $0.8 million, to $2.2 million, compared to $1.4 million for the corresponding period in the prior year. BARDA income consisted of funding from the Biomedical Advanced Research and Development Authority, under the Assistant Secretary for Preparedness and Response, within the U.S. Department of Health and Human Services, under ongoing USG Contract No. HHSO100201500028C. BARDA income increased as a result of funding by BARDA for the pivotal trial for use of the RECELL System for soft tissue reconstruction.

Total operating expenses increased by 13% or $ 5.2 million to $44.1 million, compared with $38.8 million in the corresponding period in the prior year.

Sales and marketing expenses increased by 38%, or $4.3, million to $15.6 million, compared to $11.3 million incurred in the corresponding period in the prior year. Higher costs in the current year were primarily attributed to higher pre-commercialization costs, salaries and benefits, selling expenses, and share-based compensation expenses. Higher pre-commercialization costs were incurred for planning for future RECELL launches in soft tissue reconstruction and vitiligo. Increased salaries and benefits are attributable to an increase in field personnel to further deepen the penetration within individual customer accounts. Higher selling costs were primarily due to fewer COVID-19 travel restrictions in the current year, along with higher commissions due to an increase in revenues. Higher share-based compensation expenses resulted from our granting of a long-term incentive plan to encourage and reward shareholder value creation in the business.

General and administrative expenses increased by 12%, or $2.0 million, to $18.0 million, compared to $16.0 million incurred in the same period in the prior year. The increase was primarily driven by higher salaries and benefits and share-based compensation expenses. Higher salaries and benefits were associated with expanding our workforce to support overall operations along with severance costs associated with the termination of a former executive employee. Increased share-based compensation resulted from certain performance milestones being met in the period, partially offset by the reversal of previously recognized expense for unvested awards related to the termination of an executive employee in the current year.

Research and development expenses decreased by 9%, or $1.0 million, to $10.5 million, compared to $11.5 million incurred in the same period in the prior year. Higher costs in the prior year were primarily driven by research and development costs associated with furthering the Company’s pipeline along with ramping up vitiligo clinical trial activities. The favorable variance is not a purposeful reduction in spending but reflects that certain programs were in lower cost phases during this period. The decrease in research and development was partially offset by ongoing development of a next generation device for more automated preparation of Spray-On Skin Cells in the current year.

Liquidity and Capital Resources

The Company’s short-term and long-term liquidity requirements primarily arise from funding (i) research and development expenses, (ii) general and administrative expenses including salaries, bonuses and commissions, (iii) working capital requirements. We expect to utilize cash reserves until U.S. sales of our products reach a level sufficient to fund ongoing operations. The AVITA Group has historically funded its research and development activities, and more recently its substantial investment in sales and marketing activities, through raising capital by issuing securities, and it is expected that similar funding will be obtained to provide working capital if and when required. As of September 30, 2022, the Company has sufficient cash reserves to fund operations for the next 12-months. If the Company is unable to raise capital in the future, the Company may need to curtail expenditures by scaling back certain research and development, other programs, and other expenditures.

The following table summarizes our cash flows for the periods presented (in thousands):

(In Thousands)

Nine-Months Ended September 30, 2022 September 30, 2021
Net cash used in operations $(15,654) $(13,131)
Net cash used in investing activities (16,174) (50,182)
Net cash provided by financing activities 1 64,061
Effect of foreign exchange rate on cash and cash equivalents and restricted cash (70) (29)
Net increase/(decrease) in cash and cash equivalents and restricted cash (31,897) 719
Cash and cash equivalents and restricted cash at beginning of year 55,712 59,966
Cash and cash equivalents and restricted cash at end of year 23,815 60,685

Nine-months ended September 30, 2022, and 2021.

Net cash used in operating activities was $15.7 million and $13.1 million during the nine-months ended September 30, 2022, and 2021, respectively. The increase was primarily resulted from higher operating costs.

Net cash used in investing activities was $16.2 million and $50.2 million during the nine-months ended September 30, 2022, and 2021, respectively. Cash flows used for investing activities was primarily attributable to our investments into marketable securities.

Net cash provided by financing activities was $1 thousand and $64.0 million during the nine-months ended September 30, 2022, and 2021, respectively. The decrease in cash provided by financing activities is related to proceeds from the capital raise in March 2021.

Capital management.

We aim to manage capital so that the Company continues as a going concern while also maintaining optimal returns to stockholders and benefits for other stakeholders. We also aim to maintain a capital structure that ensures the lowest cost of capital available to the Company. We regularly review the Company’s capital structure and seek to take advantage of available opportunities to improve outcomes for the Company and its stockholders.

For the period ended September 30, 2022, there were no dividends paid and we have no plans to commence the payment of dividends. We have no purchase commitments or long-term contractual obligations as of September 30, 2022. We have no committed plans to issue further shares on the market but will continue to assess market conditions and the Company’s cash flow requirements to ensure the Company is appropriately funded in order to pursue its various opportunities.

There is no significant external borrowing at the reporting date. Neither the Company nor any of the subsidiaries are subject to externally imposed capital requirement.

Off-Balance Sheet Arrangements

We have no off-balance sheet arrangements (as defined in the rules and regulations of the SEC) that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Commitments and Contractual Obligations

The Company does not have any contractual obligations or purchase commitments, except for lease obligations for the period ended September 30, 2022. For details of lease obligations refer to Note 6 in the consolidated financial statements.

Critical Accounting Estimates

There have been no material changes to our critical accounting policies and estimates from the information provided in Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in the Company’s Transition Report on Form 10-KT for the transition period ended December 31, 2021.

Controls and procedures

As filed, 1,508 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Disclosure Controls and Procedures

Our Chief Executive Officer and our Chief Financial Officer evaluated, with the participation of our management, the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q. As of September 30, 2022, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures, as defined in Securities Exchange Act Rule 13a-15(e) and 15d-15(e), were effective.

Our disclosure controls and procedures have been formulated to ensure (i) that information that we are required to disclose in reports that we file or submit under the Securities Exchange Act of 1934 was recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) that the information required to be disclosed by us is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosures.

Changes in Internal Controls over Financial Reporting

There was no change in our internal controls over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the third quarter of fiscal year 2022 covered by this Quarterly Report on Form 10-Q that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

Risk factors

As filed, 837 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

In addition to the risk factors set forth below and the other information set forth in this report, you should carefully consider the factors discussed under Part I, Item 1A, “Risk Factors” in the Company’s Transition Report on Form 10-KT for the transition period ended December 31, 2021. These factors could materially adversely affect our business, financial condition, liquidity, results of operations and capital position, and could cause our actual results to differ materially from our historical results or the results contemplated by the forward-looking statements contained in this report. There have been no material changes to the risk factors described in Part I, Item 1A, “Risk Factors,” included in our 2021 Transition Report.

Refer also to “COVID-19 Business Update and Risks Associated with COVID-19” in Part 1 above.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2022-07-01 to 2022-09-30$9.1mus-gaap:Revenues
Revenue9 months2022-01-01 to 2022-09-30$25.0mus-gaap:Revenues
Cost of revenue3 months2022-07-01 to 2022-09-30$1.5mus-gaap:CostOfRevenue
Cost of revenue9 months2022-01-01 to 2022-09-30$4.7mus-gaap:CostOfRevenue
Gross profit3 months2022-07-01 to 2022-09-30$7.6mus-gaap:GrossProfit
Gross profit9 months2022-01-01 to 2022-09-30$20.3mus-gaap:GrossProfit
Research and development3 months2022-07-01 to 2022-09-30$3.8mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2022-01-01 to 2022-09-30$10.5mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2022-07-01 to 2022-09-30−$5.7mus-gaap:OperatingIncomeLoss
Operating income9 months2022-01-01 to 2022-09-30−$21.6mus-gaap:OperatingIncomeLoss
Interest expense3 months2022-07-01 to 2022-09-30$6.0kus-gaap:InterestExpense
Interest expense9 months2022-01-01 to 2022-09-30$10.0kus-gaap:InterestExpense
Income tax3 months2022-07-01 to 2022-09-30$4.0kus-gaap:IncomeTaxExpenseBenefit
Income tax9 months2022-01-01 to 2022-09-30$12.0kus-gaap:IncomeTaxExpenseBenefit
Net income3 months2022-07-01 to 2022-09-30−$5.6mus-gaap:NetIncomeLoss
Net income9 months2022-01-01 to 2022-09-30−$21.3mus-gaap:NetIncomeLoss
Diluted EPS3 months2022-07-01 to 2022-09-30$0.22us-gaap:EarningsPerShareDiluted
Diluted EPS9 months2022-01-01 to 2022-09-30$0.85us-gaap:EarningsPerShareDiluted
Basic EPS3 months2022-07-01 to 2022-09-30$0.22us-gaap:EarningsPerShareBasic
Basic EPS9 months2022-01-01 to 2022-09-30$0.85us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2022-07-01 to 2022-09-3025,006,995 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)9 months2022-01-01 to 2022-09-3024,972,331 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow9 months2022-01-01 to 2022-09-30−$15.7mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2022-01-01 to 2022-09-30$382.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2022-09-30$23.6mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2022-09-30$91.7mus-gaap:AssetsCurrent
Total assetsAt period end2022-09-30$99.9mus-gaap:Assets
Current liabilitiesAt period end2022-09-30$9.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2022-09-30$11.7mus-gaap:Liabilities
Shareholders' equityAt period end2022-09-30$88.0mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-22-037402. Last ingested by Listed: Nov 14, 2026, 21:29 ET. Listed shows no prices and gives no investment advice.